The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population

Journal of Human Genetics

Volumn 51, Issue 10, 2006, Pages 857-863

  Liou, Ya Huei ^a   Lin, Chien Ting ^a   Wu, Ying Jye ^a   Wu, Lawrence Shih Hsin ^a  

^a VITA GENOMICS INC   (Taiwan)

Author keywords

CYP2C19; CYP2C9; CYP2D6; CYP3A4; CYP3A5; SNP; Taiwanese population

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; EXON; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METABOLITE; NUCLEOTIDE SEQUENCE; POPULATION; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TAIWAN;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN;

EID: 33749052540     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-006-0034-0     Document Type: Article

References (32)

1. Armstrong M, Fairbrother K, Idle JR, Daly AK (1994) The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 4:73-81
2. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831
3. Eckman MH, Singh SK, Erban JK, Kao G (2002) Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med Decis Making 22:108-124
4. Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann Rev Genomics Hum Genet 2:9-39
5. Evans WE, McLeod HL (2003) Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 348:538-549
6. Fukuda T, Maune H, Ikenaga Y, Naohara M, Fukuda K, Azuma J (2005) Novel structure of the CYP2D6 gene that confuses genotyping for the CYP2D6*5 allele. Drug Metab Pharmacokinet 20:345-350
7. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada J (2005) Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet 20:300-307
8. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64
9. Herrlin K, Massele AY, Jande M, Alm C, Tybring G, Abdi YA, Wennerholm A, Johansson I, Dahl ML, Bertilsson L, Gustafsson LL (1998) Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64:391-401
10. Hersberger M, Martin-Jaun J, Rentsch K, Hansler E (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 48:1072-1077
11. Hu YF, He J, Chen GL, Wang D, Liu ZQ, Zhang C, Duan LF, Zhou HH (2005) CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353:187-192
12. Jannetto PJ, Laleli-Sahin E, Wong SH (2004) Pharmacogenomic genotyping methodologies. Clin Chem Lab Med 42:1256-1264
13. Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M (2002) Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J (Engl) 115:1780-1784
14. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34
15. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA (2003) Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472
16. Meyer UA (1990) Genetic polymorphisms of drug metabolism. Fundam Clin Pharmacol 4:595-615
17. Nagata K, Yamazoe Y (2002) Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metabol Pharmacokinet 17:167-189
18. Nasu K, Kubota T, Ishizaki T (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7:405-409
19. Phillips KA, Van Bebber SL (2004) A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 5:1139-1149
20. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML, Bertilsson L (2001) Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 52:265-271
21. Ross AM, Gao R, Coyne KS, Chen J, Yao K, Yang Y, Qin X, Qian S, Yao M, TUCC Investigators (2001) A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial. Am Heart J 142:244-247
22. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
23. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450
24. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, Katada J, Hashimoto M, Matsui H, Taki K, Kaminuma T, Yamamoto M, Aida Y, Ohashi A, Ozawa N (2003) Bioinformatics research on inter-racial difference in drug metabolism. I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70
25. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931
26. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349
27. Van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671
28. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348: 529-537
29. Williams JA, Cook J, Hurst SI (2003) A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 31:1526-1531
30. Yamamoto T, Nagafuchi N, Ozeki T, Kubota T, Ishikawa H, Ogawa S, Yamada Y, Hirai H, Iga T (2003) CYP3A4(*)18: it is not rare allele in Japanese population. Drug Metab Pharmacokinet 18:267-268
31. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277-280
32. Yu HC, Chan TY, Critchley JA, Woo KS (1996) Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89:127-135